Solid shares tumble on new Duchenne drug problem
May 14, 2019 at 04:42 AM EDT
Solid Biosciences has run into yet another hurdle with its Duchenne muscular dystrophy gene therapy, disclosing Monday that the latest patient given the drug suffered a serious adverse event.
